• Clinical Insights

Caring for those with treatment-resistant depression

Aug 9th, 2023

Genoa Healthcare® can partner with you to improve outcomes for your patients living with TRD. Connect with us to get started today.

One in three adults with major depressive disorder are diagnosed with treatment-resistant depression (TRD), affecting around 1.1% of the general U.S. population. But what exactly is treatment-resistant depression? 

The term treatment-resistant depression most often refers to major depressive episodes – occurrences when symptoms of depression occur most of the day, nearly every day1 – that do not respond satisfactorily to at least two trials of optimally dosed antidepressant monotherapy. However, this definition has not yet been standardized2.

Read on to learn more about TRD and the treatment options that exist for the people you serve.

Want to learn more about TRD?

Watch Genoa Healthcare’s most recent webinar which features senior clinical pharmacist Kim Cordova, PharmD, and pharmacy operations manager Alicia Garcia Afa, PharmD, as they discuss advances in pharmacy care for individuals living with TRD.

Watch the recording below to learn more:

Let’s talk

Pharmacy expertise you deserve

Interested in learning more about how a dedicated pharmacy partner can help support positive outcomes for your consumers living with TRD? Contact us today and we’ll be in touch.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

[1] https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007

[2] https://www.uptodate.com/contents/unipolar-treatment-resistant-depression-in-adults-epidemiology-risk-factors-assessment-and-prognosis?sectionName=Treatment-resistant%20depression&topicRef=14685&anchor=H6075260&source=see_link#H6075260

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293424/

Recent Posts

  • Blog Post
A foundation to build on: 3 ways an engaged pharmacy partner helps you deliver whole-person health

A recent survey found that nearly 60% of behavioral health, primary care and complex care providers reported that their organization currently offered or had plans to begin offering integrated care...

  • Clinical Insights
  • Webinar
Understanding Tardive Dyskinesia: What you need to know

Tardive Dyskinesia (TD) – a neurological disorder associated with prolonged use of antipsychotic medications – affects over 600,000 people annually. Wondering what this means for the people you serve? Genoa...

  • Blog Post
340B 101: What your clinic needs to know

For qualified clinics and organizations, the 340B Drug Pricing Program offers savings on prescription drug costs, helping boost offerings and outcomes for people who need it most. Wondering if your...

Genoa pharmacist discussing medications with clinic partner
  • Blog Post
Back to basics: 3 benefits of partnering with a pharmacy and steps for getting started

Your team works hard to give the best care possible to the people you serve and partnering with a pharmacy can empower your staff to make an even bigger impact....